Non-invasive follow-up of urinary tract cancers

Funder	European Commission
Recipient Organization	Nova Id Fct - Associacao Para A Inovacao E Desenvolvimento Da Fct
Country	Portugal
Start Date	Jul 01, 2022
End Date	Jun 30, 2024
Duration	730 days
Number of Grantees	2
Roles	Participant; Coordinator
Data Source	European Commission
Grant ID	`101069405`

Grant Description

Bladder cancer is the most common malignancy of the urinary tract with 573,000 new cases and 213,000 deaths in 2020 worldwide and affecting more men than women in a 4:1 ratio.

Bladder cancer has the highest lifetime treatment costs per patient of all cancers, which is mainly attributed to the intensive follow-up procedures of patients after diagnostics and surgery. Follow-up is made recurring to extremely invasive and low-patient compliant tests.

ENSURE aims to validate the technological and business feasibility of the electronic nose technology developed in the ERC Starting Grant SCENT by establishing the proof-of-concept for the non-invasive follow-up of bladder cancer patients.

To accomplish this, we will approach the project from both Technical and Business perspectives, with a perfect synergy between the research and business teams, and a close contact with clinical collaborators and stakeholders.